120 related articles for article (PubMed ID: 9612134)
41. Inhibition of DNA biosynthesis by vincristine and pentoxifylline in murine P388 leukemia cells resistant to doxorubicin.
Chitnis MP; Viladkar AB; Juvekar AS
Neoplasma; 1990; 37(6):619-26. PubMed ID: 2274081
[TBL] [Abstract][Full Text] [Related]
42. Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy.
Sayed-Ahmed MM; Salman TM; Gaballah HE; Abou El-Naga SA; Nicolai R; Calvani M
Pharmacol Res; 2001 Jun; 43(6):513-20. PubMed ID: 11419959
[TBL] [Abstract][Full Text] [Related]
43. Sheng-mai-san reduces adriamycin-induced cardiomyopathy in rats.
You JS; Huang HF; Chang YL; Lee YS
Am J Chin Med; 2006; 34(2):295-305. PubMed ID: 16552840
[TBL] [Abstract][Full Text] [Related]
44. Improvements of doxorubicin-induced antitumor activity and adverse reaction by combined citrulline.
Miyashita M; Sadzuka Y
Biol Pharm Bull; 2014; 37(3):447-53. PubMed ID: 24583863
[TBL] [Abstract][Full Text] [Related]
45. The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats.
Mohamed HE; El-Swefy SE; Hagar HH
Pharmacol Res; 2000 Aug; 42(2):115-21. PubMed ID: 10887039
[TBL] [Abstract][Full Text] [Related]
46. Effect of metformin on clastogenic and biochemical changes induced by adriamycin in Swiss albino mice.
Aleisa AM; Al-Rejaie SS; Bakheet SA; Al-Bekari AM; Al-Shabanah OA; Al-Majed A; Al-Yahya AA; Qureshi S
Mutat Res; 2007 Dec; 634(1-2):93-100. PubMed ID: 17693128
[TBL] [Abstract][Full Text] [Related]
47. [Investigation of hepatoprotector Metrop GP influence on tumor growth or antitumor action of doxorubicin].
Abduloeva NKh; Stukov AN; Moiseenko VM
Vopr Onkol; 2011; 57(2):213-5. PubMed ID: 21809667
[TBL] [Abstract][Full Text] [Related]
48. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.
Gewirtz DA
Biochem Pharmacol; 1999 Apr; 57(7):727-41. PubMed ID: 10075079
[TBL] [Abstract][Full Text] [Related]
49. Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity.
Sakaguchi H; Kodama A; Tomonari M; Ando Y; Tabuchi M; To H; Araki R; Kitahara T; Sasaki H; Ohdo S; Higuchi S
Breast Cancer Res Treat; 2008 Jun; 109(3):443-50. PubMed ID: 17661173
[TBL] [Abstract][Full Text] [Related]
50. Thermosensitivity and thermotolerance in the adriamycin-resistant strain of Ehrlich ascites tumor cells.
Asaumi J; Kawasaki S; Kuroda M; Takeda Y; Hiraki Y
Anticancer Res; 1996; 16(5A):2569-73. PubMed ID: 8917353
[TBL] [Abstract][Full Text] [Related]
51. Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination.
Satoh M; Naganuma A; Imura N
Cancer Chemother Pharmacol; 1988; 21(2):176-8. PubMed ID: 3349566
[TBL] [Abstract][Full Text] [Related]
52. Membrane fluidity in Ehrlich ascites tumor cells treated with adriamycin.
Sugiyama M; Sakanashi T; Okamoto K; Chinami M; Hidaka T; Ogura R
Biotechnol Appl Biochem; 1986; 8(2-3):217-21. PubMed ID: 3741633
[TBL] [Abstract][Full Text] [Related]
53. Influence of metabolic inhibitors on the intracellular accumulation and retention of adriamycin.
Asaumi J; Kawasaki S; Kuroda M; Takeda Y; Kishi K; Hiraki Y
Anticancer Res; 1999; 19(1A):615-8. PubMed ID: 10226607
[TBL] [Abstract][Full Text] [Related]
54. In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline. Involvement of caspase cascades and IkappaBalpha phosphorylation.
Lerma-Díaz JM; Hernández-Flores G; Domínguez-Rodríguez JR; Ortíz-Lazareno PC; Gómez-Contreras P; Cervantes-Munguía R; Scott-Algara D; Aguilar-Lemarroy A; Jave-Suárez LF; Bravo-Cuellar A
Immunol Lett; 2006 Mar; 103(2):149-58. PubMed ID: 16388856
[TBL] [Abstract][Full Text] [Related]
55. In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa.
Fingert HJ; Pu AT; Chen ZY; Googe PB; Alley MC; Pardee AB
Cancer Res; 1988 Aug; 48(15):4375-81. PubMed ID: 3134125
[TBL] [Abstract][Full Text] [Related]
56. Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs.
Su J; Zhen YC; Qi CQ; Hu JL
Cancer Chemother Pharmacol; 1995; 36(2):149-54. PubMed ID: 7767952
[TBL] [Abstract][Full Text] [Related]
57. [Enhanced effect of hepatic arterial infused anticancer drugs on rabbit VX-2 carcinoma by means of combination with Lipiodol. Adriamycin versus Lipiodol adriamycin sandwich method and adriamycin suspended in a Lipiodol].
Hoshino M; Koyama Y; Sugano K; Kanno M; Satou N; Abe R
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2810-3. PubMed ID: 2551224
[TBL] [Abstract][Full Text] [Related]
58. Enhanced antitumor efficacy on hepatoma-bearing rats with adriamycin-loaded nanoparticles administered into hepatic artery.
Chen JH; Ling R; Yao Q; Wang L; Ma Z; Li Y; Wang Z; Xu H
World J Gastroenterol; 2004 Jul; 10(13):1989-91. PubMed ID: 15222053
[TBL] [Abstract][Full Text] [Related]
59. Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection.
Zeidán Q; Strauss M; Porras N; Anselmi G
J Submicrosc Cytol Pathol; 2002 Jul; 34(3):315-21. PubMed ID: 12408365
[TBL] [Abstract][Full Text] [Related]
60. Induction of antioxidants by adriamycin in mouse heart.
Yin X; Wu H; Chen Y; Kang YJ
Biochem Pharmacol; 1998 Jul; 56(1):87-93. PubMed ID: 9698092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
